Online drug pricing tools that influence consumers October 26, 2016By Mari EdlinConsumers are demanding transparency in the prices of drugs. Here’s how they are getting it.
In this issue
Obama’s precision medicine initiative: an update October 22, 2016By Judy Packer-TursmanThe precision medicine effort could dramatically change patient care, but will it be effective? New cancer care approach: Highmark’s cancer collaborative October 24, 2016By Rachael Zimlich RNCancer care has made great strides in the U.S., but effective care is still too expensive and inaccessible for many Americans. Now, payers and providers at Highmark, Allegheny Health Network and Johns Hopkins are launching a new model that could change cancer collaboration. Four things health execs should know about the oncology pipelineHere’s how you can recognize changes in the oncology pipeline and maximize value related to cancer care. Four ways the genomic data commons will advance cancer care October 20, 2016By Donna MarburyA new cancer database, the Genomic Data Commons, aims to make research more accessible Cancer MoonShot 2020 will arm oncologists with new tools October 30, 2016By Karen AppoldThe Cancer MoonShot 2020 program brings together stakeholders from pharma, community and academic oncology, as well as government and scientific communities in an effort to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients. Insurers benefit from getting on board with Cancer MoonShot 2020 October 29, 2016By Karen AppoldDrugs will be provided to health plan members on clinical trials free of charge. Effective ways I partner with my board November 07, 2016By Aubrey WestgateIndustry leaders share their go-to strategies. Independence Blue Cross president: Why we cover whole genome sequencing October 31, 2016By Daniel J. HilfertyAfter carefully considering its promise and consulting with experts, Independence Blue Cross this year became the first major insurer to provide coverage for certain members who are seeking access to whole genome sequencing.